Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx (Nasdaq: MDXG) commented on the CY 2026 Physician Fee Schedule (PFS) final rule published by CMS on Nov 3, 2025. The company says the final rule is "essentially what was proposed in July" and believes the changes and other CMS initiatives aim to reduce industry fraud, waste and abuse, restoring stability and predictability to the market.
MiMedx states it is positioned to benefit from the reform given its scalable operations, commercial reach, technology, IP portfolio, and an excellent balance sheet, while noting details and mechanics still require review and some company recommendations were not adopted.
MIMEDX (Nasdaq: MDXG) reported record third-quarter 2025 results: net sales $114M (+35% YoY), GAAP net income $17M, diluted EPS $0.11, and adjusted EBITDA $35M (31% of net sales). Gross margin was 84% and cash and cash equivalents were $142M (net cash of $124M after debt). Management raised 2025 guidance to expect mid-to-high teens net sales growth and at least mid-20% full-year adjusted EBITDA margin. Company cited CMS 2026 reimbursement rules as an open factor and will host a conference call on Oct 29, 2025 at 4:30 PM ET.
MiMedx (Nasdaq: MDXG) will report third quarter operating and financial results for the period ended September 30, 2025 after market close on Wednesday, October 29, 2025. Senior management will host a webcast and conference call beginning at 4:30 p.m. Eastern Time the same day. U.S. and international dial-in numbers and a conference ID are provided, and a replay will be available on the company website for approximately 30 days.
MiMedx (Nasdaq: MDXG) announced on October 6, 2025 the launch of EPIXPRESS, a next‑generation lyophilized human placental allograft added to its Advanced Wound Care portfolio.
EPIXPRESS is a PURION®‑processed, thick tri‑layer product that adds fenestrations to improve fluid movement versus EPIEFFECT and is intended for acute and chronic hard‑to‑heal wounds including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), deep or tunneling wounds, and wounds requiring suture fixation.
The company characterized the product as an organically developed, market‑driven innovation designed to expand clinician treatment options.
MIMEDX (NASDAQ:MDXG) has announced its participation in the Symposium on Advanced Wound Care (SAWC) Fall meeting from September 3-6, 2025 in Las Vegas. The company will host a sponsored lunch symposium titled "Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape" on September 4, 2025.
MIMEDX will showcase its advanced wound care portfolio at booth 511 and present six clinical and scientific posters focusing on various aspects of amniotic tissue applications, including pigment restoration, wound healing mechanisms, and cost-effectiveness analysis of placental allografts.
MIMEDX (NASDAQ:MDXG) has announced its participation in two upcoming investor conferences in New York. The company's senior management will present at the Cantor Global Healthcare Conference on September 3, 2025, featuring a fireside chat at 1:35 PM ET. Additionally, they will attend the Lake Street BIG9 Best Ideas Growth Conference on September 11, 2025, where they will participate in one-on-one meetings.
Interested investors can arrange meetings with MIMEDX management through their Cantor or Lake Street representatives.
MIMEDX (NASDAQ:MDXG) reported record-breaking Q2 2025 results with net sales of $99 million, marking a 13% year-over-year growth. The company achieved GAAP net income of $10 million ($0.06 per diluted share) and Adjusted EBITDA of $24 million (25% of net sales).
Growth was driven by strong performance in both segments: Wound product sales increased 12%, supported by CELERA™ and EMERGE™ products, while Surgical products grew 15%, with notable contributions from AMNIOFIX®, AMNIOEFFECT®, and HELIOGEN™. The company ended the quarter with $119 million in cash, up $12 million.
Based on strong performance, MIMEDX raised its 2025 guidance, now expecting low double-digit net sales growth and Adjusted EBITDA margin above 20%.
MIMEDX (NASDAQ:MDXG) has announced a strategic collaboration with Vaporox, establishing co-promotion and co-marketing of MIMEDX's placental allograft portfolio alongside Vaporox's Vaporous Hyperoxia Therapy (VHT) device. The partnership includes a strategic investment by MIMEDX in Vaporox and exclusive rights for potential acquisition discussions.
Vaporox's FDA-cleared VHT device combines ultrasonic mist and concentrated oxygen to treat nine types of chronic wounds, including Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers. Clinical studies have shown wound healing rates exceeding 80% at 20 weeks when VHT is combined with standard wound care, with promising results when used with MIMEDX's EPIFIX® products.
MIMEDX (NASDAQ: MDXG) has scheduled its second quarter 2025 earnings conference call for July 30, 2025. The company will release its Q2 2025 operating and financial results after market close, followed by a management-hosted webcast and conference call at 4:30 p.m. Eastern Time.
Investors can access the call through the webcast or by phone using dedicated U.S. (877-407-6184) and international (201-389-0877) numbers with conference ID 13754722. A replay will be available on the company's website for approximately 30 days after the event.
MIMEDX (NASDAQ:MDXG) has responded to CMS's proposed CY 2026 Physician Fee Schedule changes regarding skin substitute reimbursement. The new proposal suggests replacing the current ASP methodology with a fixed price of $125.38 per square centimeter for all skin substitutes.
The reform aims to address the dramatic increase in Medicare spending on skin substitutes, which surged from $1.5 billion in 2022 to nearly $10 billion in 2024. CEO Joseph H. Capper supports the reform, noting it will help combat fraud and unsavory business practices in the market.
The changes, along with the WISeR model and pending LCDs, are scheduled for implementation on January 1, 2026. MIMEDX expects to maintain its competitive position due to its product capabilities and clinical evidence.